公开(公告)号：US20170226198A1

公开(公告)日：2017-08-10

申请号：US15581448

申请日：2017-04-28

Applicant: Genentech, Inc.

Inventor： Yuanyuan XIAO ,  Carlos BAIS ,  YounJeong CHOI ,  Nicola C. CONSALVO

IPC: C07K16/22 ,  A61K39/395 ,  G01N33/574 ,  A61K31/495 ,  A61K38/21 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/22 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/57449 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2800/52 ,  A61K2300/00

Abstract: The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.